SEC Form 4 · accession 0001193125-26-256013
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Maduck
Officer — See Remarks
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 7:20 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2026 | M | 25,000 | $8.27 | A | 33,977 | D | |
| Common StockF3,F1 | Jun 1, 2026 | S | 21,069 | $70.1068 | D | 12,908 | D | |
| Common StockF4,F1 | Jun 1, 2026 | S | 3,931 | $70.7462 | D | 8,977 | D | |
| Common StockF5,F6,F1 | Jun 1, 2026 | A | 615 | $70.44 | A | 9,592 | D | |
| Common StockF7,F1 | Jun 1, 2026 | A | 615 | $0.00 | A | 10,207 | D | |
| Common StockF9,F10 | Jun 2, 2026 | F | 452 | $70.44 | D | 9,755 | D | |
| Common StockF11 | holding | — | — | — | 5,147 | I | See Footnote | |
| Common StockF12 | holding | — | — | — | 20,570 | I | See Footnote | |
| Common StockF13 | holding | — | — | — | 40,000 | I | See Footnote | |
| Common StockF14 | holding | — | — | — | 34,000 | I | See Footnote | |
| Common StockF15 | holding | — | — | — | 10,000 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F16 | $8.27 | Jun 1, 2026 | M | 25,000 | D | — | Feb 10, 2027 | Common Stock | 25,000 | 141,986 | D |
Explanation of responses
- F1Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F10Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F11Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
- F12Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
- F13Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F14Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F15Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- F16Fully exercisable.
- F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.49 to $70.48 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.49 to $70.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
- F6In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- F7Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- F8These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- F9The closing price on June 1, 2026 was used to calculate the withholding obligation.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.